



















Discovery of first-in-Class WNK3 targeted selective inhibitor for cancer immunotherapy

Checkmate Therapeutics Inc.

Disease Area	Oncology																																																																			
Product Type	Small molecule (kinase inhibitor)																																																																			
Indication	Solid tumor																																																																			
Target	WNK3 (WNK lysine deficient protein kinase 3)																																																																			
Mechanism of Action	WNK3 inhibition elicits antitumor immunity by suppressing PD-L1 expression on tumor cells and activating T-cell function																																																																			
Competitiveness	<div>1. First-in-Class WNK3 selective inhibitor</div> <div>2. Highly Potent and Selective to WNK3</div> <div>-Compound CX003 demonstrates low nM potency (IC50=21nM) of WNK3 inhibition and excellent selectivity against WNK1 (42 folds).</div> <div>3. Superior safety</div> <div>-It also shows superior cell viability in normal and immune cell line.</div> <div>4. Concurrent impact on cancer and immune cells</div> <div>-It suppresses PD-L1 in tumor cells and activates T-Cells</div>																																																																			
Development Stage	Hit																																																																			
Route of Administration	Oral administration																																																																			
Key Data	<div><div><div><div>In vitro assay</div><div><div><div><div>WNK463</div><div></div></div></div><div><div><div>CX003-0023</div><div></div></div></div></div><table><tr><th colspan="2">Compound ID</th><th>WNK-463*</th><th>CX003-0023</th></tr><tr><td rowspan="2">IC50 (nM)</td><td>WNK3</td><td>6.0</td><td>21</td></tr><tr><td>WNK1</td><td>6.0</td><td>881</td></tr><tr><td colspan="2">Folds</td><td>1.0</td><td>42</td></tr></table><div>* Pan-kinase inhibitor</div></div><div><div><div><div>Cytotoxicity</div><div><div><div>HK2</div><div></div></div></div><div><div><div>THLE</div><div></div></div></div><div><div><div>Jurkat</div><div></div></div></div></div><table><tr><th colspan="2">Compound ID</th><th>WNK-463*</th><th>CX003-0023</th></tr><tr><td rowspan="3">CC50 (nM)</td><td>HK</td><td>0.65</td><td>62</td></tr><tr><td>THLE</td><td>0.33</td><td>11</td></tr><tr><td>Jurkat</td><td>0.42</td><td>44</td></tr></table><div>* Pan-kinase inhibitor</div></div></div><div><div><div><div>PD-L1 axis</div><div><div><div><div>SNU449</div><div><table><tr><td>CX003-0023 (µM)</td><td>-</td><td>-</td><td>-</td><td>-</td><td>5</td><td>10</td></tr><tr><td>WNK463 (µM)</td><td>-</td><td>5</td><td>10</td><td>-</td><td>-</td><td>-</td></tr></table><div><div>PD-L1</div><div></div><div>Hsp90</div></div></div><div><div>SNU423</div><div><table><tr><td>CX003-0023 (µM)</td><td>-</td><td>-</td><td>-</td><td>5</td><td>10</td></tr><tr><td>WNK463 (µM)</td><td>-</td><td>5</td><td>10</td><td>-</td><td>-</td></tr></table><div><div>PD-L1</div><div></div><div>Hsp90</div></div></div></div><div><div><div>SNU201</div><div><table><tr><td>CX003-0023 (µM)</td><td>-</td><td>0.2</td><td>1</td><td>-</td><td>-</td></tr><tr><td>WNK463 (µM)</td><td>-</td><td>-</td><td>-</td><td>0.2</td><td>1</td></tr></table><div><div>PD-L1</div><div></div><div>HSP90</div></div></div></div><div>SNU449, SNU423 : Liver cancer SNU201 : GBM</div></div></div></div><div><div><div>Cytokine assay</div><div></div></div></div></div></div></div></div></div></div>	Compound ID		WNK-463*	CX003-0023	IC50 (nM)	WNK3	6.0	21	WNK1	6.0	881	Folds		1.0	42	Compound ID		WNK-463*	CX003-0023	CC50 (nM)	HK	0.65	62	THLE	0.33	11	Jurkat	0.42	44	CX003-0023 (µM)	-	-	-	-	5	10	WNK463 (µM)	-	5	10	-	-	-	CX003-0023 (µM)	-	-	-	5	10	WNK463 (µM)	-	5	10	-	-	CX003-0023 (µM)	-	0.2	1	-	-	WNK463 (µM)	-	-	-	0.2	1
Compound ID		WNK-463*	CX003-0023																																																																	
IC50 (nM)	WNK3	6.0	21																																																																	
	WNK1	6.0	881																																																																	
Folds		1.0	42																																																																	
Compound ID		WNK-463*	CX003-0023																																																																	
CC50 (nM)	HK	0.65	62																																																																	
	THLE	0.33	11																																																																	
	Jurkat	0.42	44																																																																	
CX003-0023 (µM)	-	-	-	-	5	10																																																														
WNK463 (µM)	-	5	10	-	-	-																																																														
CX003-0023 (µM)	-	-	-	5	10																																																															
WNK463 (µM)	-	5	10	-	-																																																															
CX003-0023 (µM)	-	0.2	1	-	-																																																															
WNK463 (µM)	-	-	-	0.2	1																																																															
IP																																																																				








Discovery of first-in-Class WNK3 targeted selective inhibitor for cancer immunotherapy

Checkmate Therapeutics Inc.

Disease Area	Oncology																																																																			
Product Type	Small molecule (kinase inhibitor)																																																																			
Indication	Solid tumor																																																																			
Target	WNK3 (WNK lysine deficient protein kinase 3)																																																																			
Mechanism of Action	WNK3 inhibition elicits antitumor immunity by suppressing PD-L1 expression on tumor cells and activating T-cell function																																																																			
Competitiveness	<div>1. First-in-Class WNK3 selective inhibitor</div> <div>2. Highly Potent and Selective to WNK3</div> <div>-Compound CX003 demonstrates nM potency (IC50=21nM) of WNK3 inhibition and excellent selectivity against WNK1 (42 folds).</div> <div>3. Superior safety</div> <div>-It also demonstrates enhanced safety in normal cell lines.</div> <div>4. Concurrent impact on cancer and immune cells</div> <div>-It suppresses PD-L1 in cancer cells and activates T-Cells</div>																																																																			
Development Stage	Hit																																																																			
Route of Administration	Oral administration																																																																			
Key Data	<div><div><div><div>In vitro assay</div><div><div><div><div>WNK463</div><div></div></div><div><div>CX003-0023</div><div></div></div></div><table><tr><th colspan="2">Compound ID</th><th>WNK-463*</th><th>CX003-0023</th></tr><tr><td rowspan="2">IC50 (nM)</td><td>WNK3</td><td>6.0</td><td>21</td></tr><tr><td>WNK1</td><td>6.0</td><td>881</td></tr><tr><td colspan="2">Folds</td><td>1.0</td><td>42</td></tr></table><div>* Pan-kinase inhibitor</div></div><div><div><div>Cytotoxicity</div><div><div><div>HK2</div><div></div></div><div><div>THLE</div><div></div></div><div><div>Jurkat</div><div></div></div></div><table><tr><th colspan="2">Compound ID</th><th>WNK-463*</th><th>CX003-0023</th></tr><tr><td rowspan="3">CC50 (nM)</td><td>HK</td><td>0.65</td><td>62</td></tr><tr><td>THLE</td><td>0.33</td><td>11</td></tr><tr><td>Jurkat</td><td>0.42</td><td>44</td></tr></table><div>* Pan-kinase inhibitor</div></div></div><div><div><div>PD-L1 axis</div><div><div><div>SNU449</div><div><table><tr><td>CX003-0023 (µM)</td><td>-</td><td>-</td><td>-</td><td>-</td><td>5</td><td>10</td></tr><tr><td>WNK463 (µM)</td><td>-</td><td>5</td><td>10</td><td>-</td><td>-</td><td>-</td></tr></table><div><div>PD-L1</div><div></div><div>Hsp90</div></div></div><div><div>SNU423</div><div><table><tr><td>CX003-0023 (µM)</td><td>-</td><td>-</td><td>-</td><td>5</td><td>10</td></tr><tr><td>WNK463 (µM)</td><td>-</td><td>5</td><td>10</td><td>-</td><td>-</td></tr></table><div><div>PD-L1</div><div></div><div>Hsp90</div></div></div></div><div><div>SNU201</div><div><table><tr><td>CX003-0023 (µM)</td><td>-</td><td>0.2</td><td>1</td><td>-</td><td>-</td></tr><tr><td>WNK463 (µM)</td><td>-</td><td>-</td><td>-</td><td>0.2</td><td>1</td></tr></table><div><div>PD-L1</div><div></div><div>HSP90</div></div></div></div><div>SNU449, SNU423 : Liver cancer SNU201 : GBM</div></div></div><div><div>Cytokine assay</div><div><div></div><div>IL-2 (pg/ml)</div><div>Concentration (µM)</div></div></div></div></div></div></div></div>	Compound ID		WNK-463*	CX003-0023	IC50 (nM)	WNK3	6.0	21	WNK1	6.0	881	Folds		1.0	42	Compound ID		WNK-463*	CX003-0023	CC50 (nM)	HK	0.65	62	THLE	0.33	11	Jurkat	0.42	44	CX003-0023 (µM)	-	-	-	-	5	10	WNK463 (µM)	-	5	10	-	-	-	CX003-0023 (µM)	-	-	-	5	10	WNK463 (µM)	-	5	10	-	-	CX003-0023 (µM)	-	0.2	1	-	-	WNK463 (µM)	-	-	-	0.2	1
Compound ID		WNK-463*	CX003-0023																																																																	
IC50 (nM)	WNK3	6.0	21																																																																	
	WNK1	6.0	881																																																																	
Folds		1.0	42																																																																	
Compound ID		WNK-463*	CX003-0023																																																																	
CC50 (nM)	HK	0.65	62																																																																	
	THLE	0.33	11																																																																	
	Jurkat	0.42	44																																																																	
CX003-0023 (µM)	-	-	-	-	5	10																																																														
WNK463 (µM)	-	5	10	-	-	-																																																														
CX003-0023 (µM)	-	-	-	5	10																																																															
WNK463 (µM)	-	5	10	-	-																																																															
CX003-0023 (µM)	-	0.2	1	-	-																																																															
WNK463 (µM)	-	-	-	0.2	1																																																															
IP																																																																				

Discovery of first-in-Class WNK3 targeted selective inhibitor for cancer immunotherapy

Checkmate Therapeutics Inc.

Disease Area	Oncology																										
Product Type	Small molecule (kinase inhibitor)																										
Indication	Solid tumor																										
Target	WNK3 (WNK lysine deficient protein kinase 3)																										
Mechanism of Action	WNK3 inhibition elicits antitumor immunity by suppressing PD-L1 expression on tumor cells and activating T-cell function																										
Competitiveness	<div>1. First-in-Class WNK3 selective inhibitor</div> <div>2. Highly Potent and Selective to WNK3</div> <div>-Compound CX003 demonstrates nM potency of WNK3 inhibition and excellent selectivity against WNK1.</div> <div>3. Superior safety</div> <div>-It also demonstrates enhanced safety in normal cell lines.</div> <div>4. Concurrent impact on cancer and immune cells</div> <div>-It suppresses PD-L1 in cancer cells and activates T-Cells</div>																										
Development Stage	Hit																										
Route of Administration	Oral administration																										
Key Data	<div><div><div>In vitro potency & selectivity</div><div><div><div>pan-WNK inhibitor</div></div><div><div>CX003</div></div></div></div><div><div><div>PD-L1 axis</div><div><div>SNU449 (liver cancer)</div><table><tr><td>CX003 (μM)</td><td>-</td><td>-</td><td>-</td><td>-</td><td>5</td><td>10</td></tr><tr><td>pan-WNK inh (μM)</td><td>-</td><td>5</td><td>10</td><td>-</td><td>-</td><td>-</td></tr></table><div><div>PD-L1</div></div><div><div>Hsp90</div></div></div><div><div>SNU201 (GBM)</div><table><tr><td>CX003 (μM)</td><td>-</td><td>0.2</td><td>1</td><td>-</td><td>-</td></tr><tr><td>pan-WNK inh (μM)</td><td>-</td><td>-</td><td>-</td><td>0.2</td><td>1</td></tr></table><div><div>PD-L1</div></div><div><div>HSP90</div></div></div></div></div><div><div><div>Cytokine assay</div><div><div>PBMC</div></div></div></div></div>	CX003 (μM)	-	-	-	-	5	10	pan-WNK inh (μM)	-	5	10	-	-	-	CX003 (μM)	-	0.2	1	-	-	pan-WNK inh (μM)	-	-	-	0.2	1
CX003 (μM)	-	-	-	-	5	10																					
pan-WNK inh (μM)	-	5	10	-	-	-																					
CX003 (μM)	-	0.2	1	-	-																						
pan-WNK inh (μM)	-	-	-	0.2	1																						
IP	Scheduled to applied for patent in 2026																										